The Arteries.

Not cholesterol versus sugar.

The public argument about heart disease is usually a shouting match between two camps: "it's the cholesterol" and "it's not the cholesterol, it's the sugar." The honest position — the one this series takes — is that both camps are holding a piece of the truth, and the interesting biology is in how the pieces fit. This chapter is built to hold two true things at the same time, because a map that drops either one will mislead you.

The plumbing metaphor — fat sludging up a pipe from the inside — is wrong, and it matters that it's wrong. Atherosclerosis is a disease within the wall of the artery, not a coating on its inside. Cholesterol-carrying particles cross into the wall, are trapped and oxidised there, and provoke an immune response: white blood cells move in, engorge with fat, and become the foam cells of a growing plaque.[4] The plaque builds slowly and silently, often for decades.

And the event that kills — the heart attack — is usually not a pipe finally blocking. It's a plaque rupturing: its thin cap tears, the body treats the exposed core as a wound, and a clot forms that abruptly blocks the vessel. This is why the disease is a wall problem and an inflammation problem, not just a lumen problem — and it's the doorway through which the metabolic fire does much of its damage.

The particle, not the number.

Here's the part the "it's the cholesterol" camp gets right, and the series doesn't dispute: the particles that carry cholesterol into the wall are causal. Lower them across a lifetime — by genes or by drugs — and you get less atherosclerosis. That's a genuine consensus built on genetics and trials, not a marketing line.[5]

But the number most people are told — LDL cholesterol, the amount of cholesterol inside the LDL particles — is a blunt stand-in for what actually matters: the number of particles, measured as ApoB (one ApoB molecule rides on each atherogenic particle).[2] And this is exactly where the fire enters, because insulin resistance shifts the particles toward small, dense LDL: more particles, each carrying less cholesterol. So a person can have a reassuring "normal" LDL cholesterol while carrying a high number of small, dense, wall-penetrating particles — the same measurement gap this series keeps finding, here in the lipids.

The atherogenic pattern.

Insulin resistance produces a characteristic lipid signature — so characteristic it has a name, the atherogenic dyslipidaemia, and it's one of the defining features of the metabolic syndrome:

• Triglycerides up — the liver, driven by insulin, overproduces triglyceride-rich particles.
• HDL down — the "good" cholesterol falls as a direct consequence of the high triglycerides.
• LDL made small and dense — the same machinery remodels LDL into the smaller, denser, more numerous, more wall-penetrating form.

This triad is the fingerprint of insulin resistance in the blood, and it predicts cardiovascular risk better than LDL cholesterol alone.[1] The single most useful number most people are never shown is the triglyceride-to-HDL ratio: a rough, cheap read on this whole pattern, and a decent proxy for insulin resistance itself. It's on the standard lipid panel already — just never highlighted.

The fire thins the armour.

Particles are only half the story; the wall they enter is the other half, and here insulin resistance does damage that has nothing to do with any cholesterol number. The inner lining of every artery, the endothelium, is an active organ — and one of its jobs depends on insulin. In health, insulin tells the endothelium to release nitric oxide, which relaxes and protects the vessel.[3]

Why the fire decides which plaques kill.

Because the fatal event is a plaque rupturing, not merely growing, what governs a plaque's stability matters as much as its size. Stability is an inflammation story: an inflamed plaque has a thinner, more fragile cap and a more active core, and is likelier to rupture. Insulin resistance is a chronically inflammatory state — the visceral fat, the oxidative stress of fuel overload, the glycation of chronic high glucose all feed it — so the fire raises not only how many plaques form but how dangerous each one is.[4]

Two people can carry the same plaque burden; the one whose fire is burning — inflamed, insulin-resistant — is the one whose plaque is likelier to tear. It's also why anti-inflammatory approaches to heart disease are a live and serious field: the wall's inflammation is a real, separate lever from the particles entering it.

Statins lower the number of atherogenic particles, and after a heart attack they genuinely save lives — that's not in dispute. But the metabolic reading adds the levers the statin can't pull: the number and form of the particles, the health of the endothelium, and the inflammation that governs rupture. Addressing the fire reaches all three at once.

• Lower the insulin load — reducing refined carbohydrate improves the whole atherogenic triad (triglycerides down, HDL up, LDL less dense), calms inflammation, and helps the endothelium. The one lever that reaches all the metabolic contributors together.
• Ask for the right numbers — ApoB (or at least the triglyceride-to-HDL ratio) tells you more than LDL cholesterol alone. Fasting insulin tells you whether the fire is lit.
• Keep proven cardiac treatment — none of this is a reason to refuse or stop a statin, blood-pressure drug or anti-platelet after an event; it's a reason to address the root as well.

The bullet and the armour.

Not cholesterol versus sugar. Cholesterol carried by particles that the fire makes more numerous, more dangerous, and more likely to strike a wall it has already weakened. Keep what lowers the particles — and address the insulin that shapes them and inflames the wall.

The particle is the bullet; the fire loads the gun and thins the armour. You need both to understand the wound.